SecBot SecBot
SECBOTREPLAY Home › Report › IDYA

IDYA · IDEAYA Biosciences filed a 424B5 prospectus supplement for a $300M…

IDEAYA Biosciences, Inc. · 424B5 filed Jun 8, 2026 at 16:13 ET

At the news

BEARISHIMPACT 6/10

424B5 filed Jun 8, 2026 at 16:13 ET

IDEAYA Biosciences filed a 424B5 prospectus supplement for a $300M underwritten public offering of common stock and pre-funded warrants, with an additional $45M greenshoe option. The offering comes on the heels of positive Phase 2/3 data for darovasertib in uveal melanoma presented at ASCO on June 1, a newly announced Roche collaboration for IDE892 in pancreatic cancer, and an NDA acceptance for review under the FDA's Real-Time Oncology Review program. The massive dilution (~12%+ at current share count, more with warrants exercised) is the dominant near-term factor, offsetting the positive pipeline catalysts and potentially capping upside.

  • $300 million offering of common stock and pre-funded warrants
  • Underwriters have option to purchase up to an additional $45 million of common stock
  • Last reported stock price: $28.29 on June 5, 2026
  • Net tangible book value as of March 31, 2026: $937.3 million, or $10.67 per share

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access